European Journal of Cancer
Volume 46, Issue 8 , Pages 1464-1473 , May 2010

Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomas

  • Doreen Brandt

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Xandra Volkmann

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Matthias Anstätt

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Florian Länger

      Affiliations

    • Department of Pathology, Hannover Medical School, Hannover, Germany
    • ,
  • Michael P. Manns

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Klaus Schulze-Osthoff

      Affiliations

    • Interfaculty Institute for Biochemistry, University of Tübingen, Tübingen, Germany
    • ,
  • Heike Bantel

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • Corresponding Author InformationCorresponding author: Address: Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany. Tel.: +49 511 5329514; fax: +49 511 5326998.

Received 28 November 2009 ,Revised 24 January 2010 ,Accepted 29 January 2010.

References 

  1. Chong G, Cunningham D. Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol. 2005;31:453–460
  2. Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet. 2005;365:153–165
  3. van Riel JM, van Groeningen CJ. Palliative chemotherapy in advanced gastrointestinal cancer. Eur J Gastroenterol Hepatol. 2000;12:391–396
  4. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296–1310
  5. Allen WL, Coyle VM, Johnston PG. Predicting the outcome of chemotherapy for colorectal cancer. Curr Opin Pharmacol. 2006;6:332–336
  6. Duffy MJ, van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003;39:718–727
  7. Badreddine R, Wang KK. Biomarkers in gastrointestinal cancers. Am J Gastroenterol. 2008;103:2106–2110
  8. Ferreira CG, Epping M, Kruyt FA, et al. Apoptosis: target of cancer therapy. Clin Cancer Res. 2002;8:2024–2034
  9. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798–4811
  10. Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 2005;12(Suppl 1):942–961
  11. Fischer U, Jänicke RU, Schulze-Osthoff K. Death by thousand cuts: an ever increasing list of caspase substrates. Cell Death Differ. 2003;10:76–100
  12. Ward TH, Cummings J, Dean E, et al. Biomarkers of apoptosis. Brit J Cancer. 2008;99:841–846
  13. Ueno T, Toi M, Bivén K, et al. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer. 2003;39:769–774
  14. Bantel H, Lügering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology. 2004;40:1078–1087
  15. Seidel N, Volkmann X, Länger F, et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology. 2005;42:113–120
  16. Linder S, Havelka AM, Ueno T, et al. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett. 2004;214:1–9
  17. Cummings J, Hodgkinson C, Odedra R, et al. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol Cancer Therapy. 2008;7:455–463
  18. Volkmann X, Anstaett M, Hadem J, et al. Caspase activation is associated with spontaneous recovery from acute liver failure. Hepatology. 2008;47:1624–1633
  19. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 2004;64:1751–1756
  20. Leers MP, Kölgen W, Björklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol. 1999;187:567–572
  21. Ulukaya E, Yilmaztepe A, Akgoz S, et al. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer. 2007;56:399–404
  22. Ausch C, Buxhofer-Ausch V, Olszewski U, et al. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients. Eur J Surg Oncol. 2009;35:1164–1168
  23. Prochasson P, Gunther M, Laithier M, et al. Transcriptional mechanisms responsible for the overexpression of the keratin 18 gene in cells of a human colon carcinoma cell line. Exp Cell Res. 1999;248:243–259
  24. Hendrix MJ, Seftor EA, Chu YW, et al. Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential. J Natl Cancer Inst. 1992;84:165–174
  25. Pankov R, Simcha I, Zöller M, et al. Contrasting effects of K8 and K18 on stabilizing K19 expression, cell motility and tumorigenicity in the BSp73 adenocarcinoma. J Cell Sci. 1997;110:965–974
  26. Anker P, Mulcahy H, Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies?. Int J Cancer. 2003;103:149–152
  27. Johnson PJ, Lo YM. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem. 2002;48:1186–1193
  28. Holdenrieder S, Stieber P, Bodenmüller H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer. 2001;95:114–120
  29. Renz A, Berdel WE, Kreuter M, et al. Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood. 2001;98:1542–1548
  30. Elkablawy MA, Maxwell P, Williamson K, et al. Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival. J Pathol. 2001;194:436–443
  31. Rupa JD, de Bruïne AP, Gerbers AJ, et al. Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low-turnover tumors with distinct clinical outcome. Cancer. 2003;97:2404–2411
  32. de Heer P, de Bruin EC, Klein-Kranenbarg E, et al. Dutch Colorectal Cancer Group. Caspase-3 activity predicts local recurrence in rectal cancer. Clin Cancer Res. 2007;13:5810–5815
  33. Scott LC, Evans TR, Cassidy J, et al. Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Brit J Cancer. 2009;101:410–417
  34. Olofsson MH, Ueno T, Pan Y, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res. 2007;13:3198–3206
  35. Cummings J, Ranson M, Butt F, et al. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol. 2007;60:921–924
  36. Koelink PJ, Lamers CB, Hommes DW, et al. Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer. 2009;9:88
  37. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59–73
  38. Schwerk C, Schulze-Osthoff K. Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochem Pharmacol. 2003;66:1453–1458
  39. Green DR, Ferguson T, Zitvogel L, et al. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009;9:353–363
  40. Gamrekelashvili J, Krüger C, von Wasielewski R, et al. Necrotic tumor cell death in vivo impairs tumor-specific immune responses. J Immunol. 2007;178:1573–1580
  41. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691–1701
  42. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61

PII: S0959-8049(10)00090-0

doi: 10.1016/j.ejca.2010.01.037

European Journal of Cancer
Volume 46, Issue 8 , Pages 1464-1473 , May 2010

Article Tools

* Image Usage & Resolution